Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA

Ítems similars

• Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies
  per: Paul G. Richardson, et al.
  Publicat: (2024-11-01)
• P968: ALLOCATION AND VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM IN THE ICARIA-MM AND IKEMA STUDIES
  per: Aurore Perrot, et al.
  Publicat: (2023-08-01)
• Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA
  per: Tom Martin, et al.
  Publicat: (2022-06-01)
• Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
  per: Thomas Martin, et al.
  Publicat: (2023-05-01)
• Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
  per: Thomas Martin, et al.
  Publicat: (2023-09-01)